Standard

Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. / Desheva, J. A.; Lu, X. H.; Rekstin, A. R.; Rudenko, L. G.; Swayne, D. E.; Cox, N. J.; Katz, J. M.; Klimov, A. I.

In: Vaccine, Vol. 24, No. 47-48, 17.11.2006, p. 6859-6866.

Research output: Contribution to journal › Article › peer-review

Harvard

Desheva, JA, Lu, XH, Rekstin, AR, Rudenko, LG, Swayne, DE, Cox, NJ, Katz, JM & Klimov, AI 2006, 'Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential', Vaccine, vol. 24, no. 47-48, pp. 6859-6866. https://doi.org/10.1016/j.vaccine.2006.06.023

APA

Desheva, J. A., Lu, X. H., Rekstin, A. R., Rudenko, L. G., Swayne, D. E., Cox, N. J., Katz, J. M., & Klimov, A. I. (2006). Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine, 24(47-48), 6859-6866. https://doi.org/10.1016/j.vaccine.2006.06.023

Vancouver

Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, Cox NJ et al. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine. 2006 Nov 17;24(47-48):6859-6866. https://doi.org/10.1016/j.vaccine.2006.06.023

Author

Desheva, J. A. ; Lu, X. H. ; Rekstin, A. R. ; Rudenko, L. G. ; Swayne, D. E. ; Cox, N. J. ; Katz, J. M. ; Klimov, A. I. / Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. In: Vaccine. 2006 ; Vol. 24, No. 47-48. pp. 6859-6866.

BibTeX

@article{568d0d86f48f4b18a62dadb037d9c272,
title = "Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential",
abstract = "We generated a high-growth 7:1 reassortant (Len17/H5) that contained the hemagglutinin (HA) gene from non-pathogenic A/Duck/Potsdam/1402-6/86 (H5N2) virus and other genes from the cold-adapted (ca) attenuated A/Leningrad/134/17/57 (H2H2) strain. Len17/H5 demonstrated an attenuated phenotype in mice and did not infect chickens. Mice administered Len17/H5 either as a live-attenuated intranasal vaccine or as an inactivated intramuscular vaccine were substantially protected from lethal challenge with highly pathogenic A/Hong Kong/483/97 (H5N1) virus and were protected from pulmonary infection with antigenically distinct A/Hong Kong/213/2003 (H5N1) virus. The cross-protective effect correlated with the levels of virus-specific mucosal IgA and/or serum IgG antibodies. Our results suggest a new strategy of using classical genetic reassortment between a high-growth ca H2N2 strain and antigenically related non-pathogenic avian viruses to prepare live-attenuated and inactivated vaccines for influenza pandemic.",
keywords = "Avian influenza vaccine, Influenza pandemic, Mouse model",
author = "Desheva, {J. A.} and Lu, {X. H.} and Rekstin, {A. R.} and Rudenko, {L. G.} and Swayne, {D. E.} and Cox, {N. J.} and Katz, {J. M.} and Klimov, {A. I.}",
year = "2006",
month = nov,
day = "17",
doi = "10.1016/j.vaccine.2006.06.023",
language = "English",
volume = "24",
pages = "6859--6866",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "47-48",

}

RIS

TY - JOUR

T1 - Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential

AU - Desheva, J. A.

AU - Lu, X. H.

AU - Rekstin, A. R.

AU - Rudenko, L. G.

AU - Swayne, D. E.

AU - Cox, N. J.

AU - Katz, J. M.

AU - Klimov, A. I.

PY - 2006/11/17

Y1 - 2006/11/17

N2 - We generated a high-growth 7:1 reassortant (Len17/H5) that contained the hemagglutinin (HA) gene from non-pathogenic A/Duck/Potsdam/1402-6/86 (H5N2) virus and other genes from the cold-adapted (ca) attenuated A/Leningrad/134/17/57 (H2H2) strain. Len17/H5 demonstrated an attenuated phenotype in mice and did not infect chickens. Mice administered Len17/H5 either as a live-attenuated intranasal vaccine or as an inactivated intramuscular vaccine were substantially protected from lethal challenge with highly pathogenic A/Hong Kong/483/97 (H5N1) virus and were protected from pulmonary infection with antigenically distinct A/Hong Kong/213/2003 (H5N1) virus. The cross-protective effect correlated with the levels of virus-specific mucosal IgA and/or serum IgG antibodies. Our results suggest a new strategy of using classical genetic reassortment between a high-growth ca H2N2 strain and antigenically related non-pathogenic avian viruses to prepare live-attenuated and inactivated vaccines for influenza pandemic.

AB - We generated a high-growth 7:1 reassortant (Len17/H5) that contained the hemagglutinin (HA) gene from non-pathogenic A/Duck/Potsdam/1402-6/86 (H5N2) virus and other genes from the cold-adapted (ca) attenuated A/Leningrad/134/17/57 (H2H2) strain. Len17/H5 demonstrated an attenuated phenotype in mice and did not infect chickens. Mice administered Len17/H5 either as a live-attenuated intranasal vaccine or as an inactivated intramuscular vaccine were substantially protected from lethal challenge with highly pathogenic A/Hong Kong/483/97 (H5N1) virus and were protected from pulmonary infection with antigenically distinct A/Hong Kong/213/2003 (H5N1) virus. The cross-protective effect correlated with the levels of virus-specific mucosal IgA and/or serum IgG antibodies. Our results suggest a new strategy of using classical genetic reassortment between a high-growth ca H2N2 strain and antigenically related non-pathogenic avian viruses to prepare live-attenuated and inactivated vaccines for influenza pandemic.

KW - Avian influenza vaccine

KW - Influenza pandemic

KW - Mouse model

UR - http://www.scopus.com/inward/record.url?scp=33846240928&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.06.023

DO - 10.1016/j.vaccine.2006.06.023

M3 - Article

C2 - 17050041

AN - SCOPUS:33846240928

VL - 24

SP - 6859

EP - 6866

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 47-48

ER -

ID: 99383249